Interest in the Use of Dressings With Honey for Wound Healing After Excision of Pilonidal Cyst (Pilomiel)

November 14, 2025 updated by: Centre Hospitalier Departemental Vendee
The management of pilonidal cysts is a skin excision and under deep skin. Scarring requires regular dressings (daily for 15 days and then every 48 hours) until complete healing. This healing is obtained on average in 68 days. Some patients have difficulties in healing with a final healing achieved on average in 95 days. Some teams use honey to promote wound cavitary wounds (wound infection, pressure ulcers, varicose wound). The acceleration of wound healing is due to antibacterial properties and hyperosmolarity to reduce secretions. ) The use of honey in pilonidal cysts is not evaluated and may accelerate healing.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

890

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • La Roche-sur-Yon, France, 85925
        • Centre Hospitalier Departemental Vendee

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Cavity Wound to 6 weeks of a pilonidal cyst excision
  • Bloodless wound
  • Pilonidal cyst not recurred
  • Age : 18 years and older
  • Signature of informed consent
  • In the capacity to understand the study

Exclusion Criteria:

  • Bleeding wound
  • Refused to participate in Protocol
  • Patient immunocompromised
  • Recurrent pilonidal cyst
  • Patients on long-term corticosteroid
  • Patient deprived of liberty, under guardianship
  • Patient unable to understand the study
  • Allergy or hypersensitivity to honey
  • Allergy Or hypersensitivity to hyaluronic acid
  • Allergy or hypersensitivity to guar gum
  • Allergy or hypersensitivity to pectin
  • Known allergy to propolis (potentially present in honey)
  • Sensitivity to zinc oxide
  • Sensitivity known dressings used in this trial or any component
  • Diabetes Non-insulin or insulin

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: standard dressings with sterile honey
Melectis G
Device: Melectis G
No Intervention: standard dressings

In general, the dressings made are either of the type :

  • Algosteril® (round or flat wick) + Mepilex® border
  • or AquacelTM ExtraTM + AquacelTM Foam

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Healing Time
Time Frame: from randomization to 180 days maximum
from randomization to 180 days maximum

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Departemental Vendee

Investigators

  • Principal Investigator: Emeric ABET, PH, Centre Hospitalier Departemental Vendee

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 8, 2016

Primary Completion (Actual)

February 10, 2022

Study Completion (Actual)

February 10, 2022

Study Registration Dates

First Submitted

June 26, 2015

First Submitted That Met QC Criteria

June 26, 2015

First Posted (Estimated)

June 30, 2015

Study Record Updates

Last Update Posted (Estimated)

December 2, 2025

Last Update Submitted That Met QC Criteria

November 14, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHD018-15

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pilonidal Cysts

Clinical Trials on Melectis G

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe